Request Demo

Last update 13 May 2026

Beclometasone Dipropionate

Last update 13 May 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione, 9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, 9-chloro-16β-methyl-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate

+ [49]

Target

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [2]

Active Indication

Rhinitis, Allergic, SeasonalAsthmaRhinitis, Allergic+ [1]

Inactive Indication

Acute Graft Versus Host DiseaseAcute sinusitisBronchial Hyperreactivity+ [16]

Originator Organization

Merck & Co., Inc.

Active Organization

Guangdong San Lan Pharmaceutical Co. Ltd.

Soligenix, Inc.

Zhejiang Xianju Pharmaceutical Co., Ltd.

+ [3]

Inactive Organization

CHIESI Farmaceutici SpAAllergan UCSchering Corp.

+ [4]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (12 May 1976),

AsthmaRhinitis, Allergic

Regulation-

Structure/Sequence

Molecular FormulaC28H37ClO7

InChIKeyKUVIULQEHSCUHY-XYWKZLDCSA-N

CAS Registry5534-09-8

197

Clinical Trials associated with Beclometasone Dipropionate

CTR20260528

/ Active, not recruitingNot Applicable

丙酸倍氯米松吸入气雾剂在中国健康试验参与者中的单次给药、随机、开放、四周期、完全重复交叉、空腹状态下的生物等效性试验

[Translation] Bioequivalence study of beclomethasone dipropionate inhalation aerosol in healthy Chinese participants: a single-dose, randomized, open-label, four-period, fully replicated crossover trial under fasting conditions.

主要研究目的：评价合肥力成药业有限公司研制的丙酸倍氯米松吸入气雾剂与Chiesi Limited持证的丙酸倍氯米松吸入气雾剂（商品名：Clenil® Modulite®）单次空腹吸入给药在中国健康试验参与者中的生物等效性。次要研究目的：评价空腹状态下丙酸倍氯米松吸入气雾剂受试制剂和参比制剂在中国健康试验参与者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of a single-dose, fasting inhalation of beclomethasone dipropionate inhalation aerosol developed by Hefei Licheng Pharmaceutical Co., Ltd., and that of a single-dose, fasting inhalation of beclomethasone dipropionate inhalation aerosol (trade name: Clenil® Modulite®) certified by Chiesi Limited in healthy participants in a Chinese health trial. Secondary objective: To evaluate the safety of the test and reference formulations of beclomethasone dipropionate inhalation aerosol in healthy participants in a fasting state.

Start Date14 Mar 2026

Sponsor / Collaborator

Hefei Licheng Pharmaceutical Co., Ltd.

CTR20260266

/ CompletedNot Applicable

吸入用丙酸倍氯米松混悬液的生物等效性试验

[Translation] Bioequivalence study of inhaled beclomethasone dipropionate suspension

主要目的：在健康参与者体内，在空腹条件下，以Chiesi Farmaceutici S.p.A. 持有的吸入用丙酸倍氯米松混悬液（规格：2 ml:0.8 mg；商品名：宝丽亚®）为参比制剂，研究河北汇德旭盛医药科技有限公司持有的吸入用丙酸倍氯米松混悬液（规格：2 ml:0.8 mg；受试制剂）的药代动力学，评价受试制剂与参比制剂是否具有生物等效性。次要目的：观察受试制剂和参比制剂在健康参与者中的安全性。

[Translation]

Primary Objective: To investigate the pharmacokinetics of beclomethasone dipropionate inhalation suspension (2 ml: 0.8 mg; trade name: Baoliya®) manufactured by Chiesi Farmaceutici S.p.A., under fasting conditions in healthy participants, and to evaluate the bioequivalence of the test formulation with the reference formulation. Secondary Objective: To observe the safety of the test and reference formulations in healthy participants.

Start Date28 Feb 2026

Sponsor / Collaborator

Hebei Huide Xusheng Pharmaceutical Technology Co., Ltd

ChiCTR2600118322

/ SuspendedEarly Phase 1

A randomized, open-label, controlled, proof of concept trial to evaluate the efficacy of extra fine particle inhaled triple therapy in preventing progression to COPD in high-risk individuals with pre-COPD: a study protocol

Start Date09 Feb 2026

Sponsor / Collaborator-

100 Clinical Results associated with Beclometasone Dipropionate

100 Translational Medicine associated with Beclometasone Dipropionate

100 Patents (Medical) associated with Beclometasone Dipropionate

3,878

Literatures (Medical) associated with Beclometasone Dipropionate

01 May 2026·ENVIRONMENTAL RESEARCH

Bisphenol A bis (diphenyl phosphate) disrupts tryptophan metabolism through microbiota dysbiosis to promote intestinal toxicity

Article

Author: Ye, Yongxiu ; Lyu, Yang ; Zhong, Wenjue ; Zhang, Chi ; Zhu, Lingyan

Organophosphorus flame retardants (OPFRs) are associated with intestinal injury. Bisphenol A bis(diphenyl phosphate) (BDP), an emerging OPFR that presents widely in organisms and humans, may induce intestinal toxicity, yet the effect and underlying mechanism remains unclear. In this study, zebrafish were exposed to BDP at 2, 20 and 200 μg/L for 21 days. Distinct histopathological changes in the intestine of zebrafish were observed, and the relative expressions of mucus secretion and tight junction related genes (MUC-2, Occuludin a and ZO-1) were all downregulated. Through the integrated analysis combining metabolomics and metagenomics, the results demonstrated that BDP exposure downregulated the abundances of microbiota Peptostreptococcus, Clostridium, Bombilactobacillus and Sporolactobacillus in zebrafish intestines, to depress tryptophan metabolism and eventually reduce the abundances of tryptophan metabolites. As a result, the expression of AhR, an important receptor activated by tryptophan metabolites, was inhibited to downregulate IL-22 expression, promoting intestinal toxicity. In vivo experiment with indole-3-propionic acid supplement alleviated the pathological changes, which further confirmed that BDP destroyed microbiota-tryptophan metabolism homeostasis to interfere with the AhR-IL-22 axis, eventually promoted pathological toxicity in the intestines. This study highlights vulnerability of intestines to BDP, and provides first insight into the mechanism through which BDP threats intestinal health.

01 Apr 2026·RESPIRATORY MEDICINE

BDP/FF/GB single-inhaler triple therapy in COPD: real-world effectiveness, safety, and adherence in a pooled analysis of 5,000 patients

Article

Author: Franzini, Laura ; Rogliani, Paola ; Nudo, Elena ; Bakakos, Petros ; Piraino, Alessio ; Brusselle, Guy ; Di Palma, Luca ; Stolz, Daiana

BACKGROUND:

Chronic Obstructive Pulmonary Disease (COPD) represents a major global health challenge, frequently necessitating triple therapy for patients unresponsive to dual bronchodilation. Single-inhaler triple therapy (SITT) combining beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) offers a practical and effective solution with potential adherence benefits in real-world settings.

METHODS:

This pooled analysis included patient-level data from six European prospective observational studies assessing the real-world effectiveness and safety of BDP/FF/GB SITT in COPD patients over 6 months. Outcomes included changes in health-related quality of life (HRQoL; measured by COPD Assessment Test [CAT] scores), lung function (FEV₁), and adherence, with safety and exacerbation rates assessed through 12 months. Subgroup comparisons based on prior therapy, exacerbation history, and disease severity were also performed.

RESULTS:

Among 5523 patients enrolled, 4541 were included in the full analysis set. Significant improvements in HRQoL were observed, with mean CAT score reductions of -3.8 and -4.7 at months 3 and 6, respectively (p < 0.0001). Patients with at least one exacerbation decreased from 93.1% (pre-treatment) to 35.7% at 12 months (p < 0.0001). FEV₁ improvements were observed up to 6 months, with over 40% of patients achieving ≥100 mL increase. Adherence significantly improved, with poor-adherence patients transitioning to higher categories over time. Logistic regression identified poor baseline adherence (vs. good), ex-smokers (vs non-smokers), and experiencing two (vs. >2) exacerbations as predictors of treatment response. Adverse events were reported by 21.9% of patients.

CONCLUSION:

Extrafine BDP/FF/GB SITT demonstrated significant real-world safety and effectiveness in improving symptoms, lung function, and adherence.

04 Mar 2026·JOURNAL OF ASTHMA

Improved lung function with beclomethasone/formoterol versus beclomethasone alone in asthma: the FORCE2 study

Article

Author: Cretarola, Lorenza ; Weinstein, Steven ; Legramandi, Lorenzo ; Hernandez, Gemzel ; Foti, Martina ; Seregni, Lucio ; Gandini, Giuliana ; Mathews, Kusum S. ; Passineau, Heather ; Skloot, Gwen

OBJECTIVE:

This study aimed to confirm the efficacy and safety of the inhaled fixed-dose combination of beclomethasone dipropionate (BDP) plus formoterol fumarate (FF) vs. BDP in patients with asthma.

METHODS:

After a two-week run-in period with asthma maintenance therapy switched to BDP via pressurized metered-dose inhaler (pMDI), eligible patients were randomized to BDP/FF or BDP, both via pMDI, for 12 wk. The primary objective was to demonstrate superiority of BDP/FF over BDP for change from baseline at Week 12 in area under the curve between 0 and 12 h post-dose (AUC_0-12h) of forced expiratory volume in 1 sec (FEV₁). The key secondary objective was to demonstrate superiority of BDP/FF over BDP for change from baseline at Week 12 in peak FEV₁ within the first 3 h post-dose. Safety and tolerability were assessed as secondary endpoints.

RESULTS:

Of 576 patients randomized to treatment, 543 completed the study (BDP/FF: 276/287 [96.2%]; BDP: 267/289 [92.4%]). The primary and the key secondary objectives were met, with BDP/FF vs. BDP adjusted mean differences of 104 (95% confidence interval 61, 148) mL and 124 (76, 173) mL for FEV₁ AUC_0-12h and peak FEV₁ at Week 12, respectively (p < 0.001 for both). A similar proportion of patients experienced adverse events in the two treatment groups (26.9% vs. 26.4%), with most events mild or moderate in severity and not considered related to study drug.

CONCLUSIONS:

The study met its aims, demonstrating the contribution of FF to BDP in lung function improvement, with both treatments being well tolerated.ClinicalTrials.gov NCT05292586.

News (Medical) associated with Beclometasone Dipropionate

01 May 2026

·www.prnewswire.com

Berman Tabacco, Sperling Kenny Nachwalter, LLC and Hilliard Shadowen LLP Announce a Class Action Settlement If You Purchased, Paid For, or Provided Reimbursement for QVAR® and/or QVAR RediHaler® Inhalers From January 1, 2015 through July 31, 2025

SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Legal Notice Did You Purchase, Pay for, or Provide Reimbursement for QVAR® and/or QVAR RediHaler® Inhalers? You Could Get Money from a Settlement. There is a Settlement in a class action lawsuit with Teva Pharmaceutical Industries Ltd.; Teva Pharmaceuticals USA, Inc.; Teva Branded Pharmaceutical Products R&D, Inc.; and Norton (Waterford) Ltd. (collectively, "Teva"). The lawsuit claims that Teva unlawfully kept generic versions of QVAR® and QVAR RediHaler® off the market, so consumers and third-party payors paid more for QVAR® and QVAR RediHaler® inhalers than they should have. Teva denies it did anything wrong. No one is claiming that QVAR® or QVAR RediHaler® Products are unsafe. Who is included in the Settlement? You may be included in the Settlement if you are a person or entity that, for consumption by yourself, your families, or your members, insureds, or beneficiaries, purchased, paid, and/or provided reimbursement for some or all of the purchase price of QVAR® and/or QVAR RediHaler® inhalers, from January 1, 2015, through July 31, 2025, other than for resale, in the following states and territories: Alaska, Arkansas, Arizona, California, Connecticut, Delaware, D.C., Florida, Hawaii, Illinois, Indiana, Iowa, Kansas, Maine, Massachusetts, Maryland, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Vermont, Washington, West Virginia, Wisconsin, and Wyoming. A more detailed notice, including the full class definition and who is not included, is available at . What does the Settlement provide? Teva will pay $35 million into a Settlement Fund that will pay (1) money to eligible Class Members; (2) notice and administration costs; (3) service awards to the class representatives who brought the lawsuit; and (4) attorneys' fees, costs, and expenses. Teva will also remove/delist certain patents from the Food and Drug Administration's Orange Book, removing certain barriers to bringing generic versions of QVAR® to market. How can I get a payment? You must submit a valid Claim Form to apply for payment from the Settlement Fund. The amount of your payment will depend on the amount of QVAR® and QVAR RediHaler® products you purchased, the number of valid claims filed, and the amount of purchases represented by those valid claims. Claim Forms, and information on how to submit them, are available at . Claim Forms must be postmarked (if mailed) or received (if submitted online) on or before July 31, 2026 . What are my rights? Even if you do nothing, you will be bound by the Court's decisions. If you want to keep your right to sue Teva yourself, you must exclude yourself by June 15, 2026. If you do not exclude yourself, you may object to the Settlement by June 15, 2026. Detailed instructions about how to act on these rights are available at . The Court will hold a hearing on August 5, 2026 to consider whether to approve the Settlement, a request for attorneys' fees of up to 33% of the Settlement Fund, reimbursement of litigation costs and expenses up to $890,000, payment of reasonable notice and claims administration costs, and service awards of $25,000 to each of the four class representatives. You or your own lawyer may appear and speak at the hearing at your own expense. The Court may change these deadlines or the hearing date and time. Check the website below for updates. Please do not call the Court or the Clerk of the Court for information about the Settlement. For more information: 1-866-588-8524 SOURCE Berman Tabacco, Sperling Kenny Nachwalter, LLC and Hilliard Shadowen LLP 21% more press release views with Request a Demo

Patent Infringement

14 Apr 2026

·www.biospace.com

Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.

Launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol, two widely prescribed respiratory products that were approved by the Food and Drug Administration (FDA) in 2025. These are the Company’s first two metered-dose inhalation (MDI) product launches in the U.S., marking Amneal’s entry into the complex inhalation category. Albuterol sulfate inhalation aerosol (90 mcg per actuation) is a generic equivalent of PROAIR ® HFA. Beclomethasone dipropionate HFA inhalation aerosol (40 mcg and 80 mcg per actuation) is a generic equivalent of the original QVAR ® Inhalation Aerosol, 40 mcg and 80 mcg. Both products utilize the hand-breath actuator device in which the cannister is depressed by the patient before inhaling. This option was previously discontinued for QVAR ® , creating a potential gap in patient choice. “The launch of these two important inhalation products marks a significant milestone for Amneal and underscores the continued expansion of our respiratory platform,” said Dr. Srinivas Kone, Senior Vice President and Chief Scientific Officer – Affordable Medicines. “Manufactured at our dedicated inhalation facility in Ireland, these complex products reflect our ability to develop and scale difficult-to-make formulations that address meaningful gaps in patient access. With multiple additional inhalation products in active development, we are building a durable and differentiated presence in this attractive category.” Product Information Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. The most common adverse reactions reported with the use of albuterol sulfate inhalation aerosol (≥3.0% and greater than placebo) include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis. For full prescribing information, see package insert here . Beclomethasone dipropionate HFA inhalation aerosol is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. It is not indicated for the relief of acute bronchospasm. The most common adverse reactions reported with the use of beclomethasone dipropionate HFA inhalation aerosol include headache, pharyngitis, upper respiratory tract infection, rhinitis, increased asthma symptoms, and sinusitis. For full prescribing information, please refer to the package insert here . According to IQVIA ® U.S. annual sales data, for the 12 months ended February 2026, albuterol sulfate inhalation aerosol had sales of approximately $1.5 billion, and beclomethasone dipropionate HFA inhalation aerosol had sales of approximately $321 million. All trademarks are property of their respective owners. About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more, please visit and follow us on LinkedIn . Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. Investor Contact Anthony DiMeo VP, Investor Relations anthony.dimeo@amneal.com Media Contact Brandon Skop Sr. Director, Corporate Communications brandon.skop@amneal.com

Drug Approval

02 Dec 2025

·www.globenewswire.com

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

Represents second complex respiratory therapeutic product approval in Q4 2025BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s albuterol sulfate inhalation aerosol (90 mcg per actuation). The product is the generic equivalent of PROAIR® HFA (albuterol sulfate inhalation aerosol), a registered trademark of Teva Respiratory LLC. This approval follows the Company’s FDA approval of its beclomethasone dipropionate inhalation aerosol, a generic equivalent of QVAR® (beclomethasone dipropionate inhalation aerosol), further advancing Amneal’s entry into complex inhaled and respiratory drug delivery. Together, these milestones underscore the Company’s momentum in building a differentiated, high-value respiratory portfolio supported by its state-of-the-art manufacturing platform. “Securing two significant inhalation approvals this quarter—first beclomethasone dipropionate and now albuterol—highlights the tremendous progress our teams have made in a highly complex respiratory category,” said Dr. Srinivas Kone, Senior Vice President, Chief Scientific Officer – Affordable Medicines. “These achievements are the result of years of hard work, engineering excellence, and investment in our respiratory platform, and they position Amneal to deliver meaningful growth and patient impact.” Albuterol sulfate inhalation aerosol is indicated for the treatment or prevention of bronchospasm in adults and children 12 years of age and older with reversible obstructive airway disease. The most common adverse reactions (≥3.0% and >placebo) are headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis. For full prescribing information, see package insert here. According to IQVIA® U.S. annual sales for albuterol sulfate inhalation aerosol for the 12 months ended September 2025 were approximately $1.5 billion. PROAIR® HFA and QVAR® are registered trademarks of Teva Respiratory LLC. About AmnealAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn. Cautionary Statement on Forward-Looking StatementsCertain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. Investor Contact Anthony DiMeoVP, Investor Relations anthony.dimeo@amneal.com Media ContactBrandon SkopSr. Director, Corporate Communicationsbrandon.skop@amneal.com

Drug Approval

100 Deals associated with Beclometasone Dipropionate

External Link

KEGG	Wiki	ATC	Drug Bank
D00689	Beclometasone Dipropionate	D07AC15 R03BA01 R01AD01	DB00394

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Rhinitis, Allergic, Seasonal	United States	Teva Branded Pharmaceutical Products R&D LLC	23 Mar 2012
Rhinitis, Vasomotor	Japan	Sumitomo Pharmaceuticals Co., Ltd.	01 Oct 1999
Asthma	United States	Schering Corp.	12 May 1976
Rhinitis, Allergic	United States	Schering Corp.	12 May 1976

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 3	China	CHIESI Farmaceutici SpA	30 Jul 2018
Acute sinusitis	Phase 3	Italy	CHIESI Farmaceutici SpA	01 Jan 2013
Obstructive bronchitis	Phase 3	Italy	CHIESI Farmaceutici SpA	07 Aug 2012
Pneumonia	Phase 3	Italy	CHIESI Farmaceutici SpA	07 Aug 2012
Croup	Phase 3	Italy	CHIESI Farmaceutici SpA	01 Apr 2010
Acute Graft Versus Host Disease	Phase 3	United States	Soligenix, Inc.	01 Oct 2009
Rhinitis, Allergic, Perennial	Phase 3	United States	Teva Pharmaceutical Industries Ltd.	01 Oct 2009
Colitis, Ulcerative	Phase 3	Belgium	CHIESI Farmaceutici SpA	04 Dec 2007
Persistent asthma	Phase 3	Austria	CHIESI Farmaceutici SpA	01 Aug 2002
Persistent asthma	Phase 3	Italy	CHIESI Farmaceutici SpA	01 Aug 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03888131 (FORSYYN, CTgov)	Phase 3	Pulmonary Disease, Chronic Obstructive	750	placebo+beclometasone dipropionate+formoterol fumarate+CHF 1535+Symbicort (CHF 1535 100/6 µg pMDI - ITT Population)	isjwbbkcmq(hnvdpkdost) = acvvwsrhhq uwjjmrurdt (yvyisnbnpb, gleccenwvo - rusyfwhban) View more	-	12 May 2026
				placebo+budesonide+formoterol fumarate+CHF 1535+Symbicort (Symbicort® Turbohaler® - ITT Population)	isjwbbkcmq(hnvdpkdost) = wzbcxfdeld uwjjmrurdt (yvyisnbnpb, lacaulmcds - fenbjgninp) View more
NCT05970731 (CTgov)	Phase 2	Anosmia	16	Microsponge+Beclomethasone (Beclomethasone)	nhjfavlkfk = tqmhkdtaft moyrqvplsu (mosbvshvcw, ogclfzmwzf - hvlkzjoqic) View more	-	19 Mar 2026
				Microsponge (Placebo)	nhjfavlkfk = djwqthubyo moyrqvplsu (mosbvshvcw, slhuyhitos - rgcbwkwykr) View more
NCT05292586 (FORCE2, Pubmed \| J Asthma)	Phase 3	Asthma	543	beclomethasone/formoterol	pezfkxmjpv(prehqebmlv) = fblvwharub dehrhrvery (eavlkjfgoh )	Positive	22 Nov 2025
				beclomethasone	pezfkxmjpv(prehqebmlv) = apzteealph dehrhrvery (eavlkjfgoh )
NCT04294641 (CTgov)	Phase 2	Chronic graft-versus-host disease	10	Ibrutinib	zmmdhsmukb = tyewsezzil hsdzlqjtqv (uyftoxobtl, kganoekupv - iyahvjnjta) View more	-	22 Jan 2025
NCT03886441 (ESMO2024) Manual	Phase 2	Locally Advanced Lung Non-Small Cell Carcinoma	292	Belomethason propionate inhalation	jevrnonrie(zwtlhmhbmq) = brdiqgbodq jukqavopei (apiozrultg ) View more	Positive	16 Sep 2024
				belomethason propionate inhalation (Control (no inhalation))	jevrnonrie(zwtlhmhbmq) = uyxnfztozg jukqavopei (apiozrultg ) View more
NCT02517099 (PrIGMa, CTgov)	Phase 2	Asthma \| Inflammation \| Infectious Diseases	60	Beclometasone+Azithromycin+Co-amoxiclav (Pathological Phenotype)	pdctfzuhwd(czrdedzszh) = ndoeqlwucp comrhxqisx (qbvojnkhzh, diuhxrhhra - kcapuxqhbv) View more	-	06 Mar 2023
				Beclometasone+Azithromycin+Co-amoxiclav (Clinical Guidelines)	pdctfzuhwd(czrdedzszh) = iizjqezbml comrhxqisx (qbvojnkhzh, ryvubionzf - bdjuyqqbph) View more
NCT02351180 (CTgov)	Phase 1/2	Lung transplant rejection \| Viral respiratory infection	16	Inhaled beclomethasone (Inhaled Beclomethasone)	xbkmyooaqd = qqqwirquuh fvstkhdqeh (klgiykmmix, ddtzmtkpow - yfkvmsomgd) View more	-	03 Mar 2022
				Placebo (Placebo)	xbkmyooaqd = fyvhmugbex fvstkhdqeh (klgiykmmix, tumgusdsbo - piosidenmv) View more
NCT03084718 (BEAM, CTgov)	Phase 2	Asthma	610	CHF (Treatment A (CHF 718 pMDI 100 µg TDD))	adugiwbnyp(pcuihqmvfd) = qropjmzeyt jllwmaenep (zgdcjdroju, jzkldqzwtd - xxparrhdkj) View more	-	14 Dec 2021
				CHF (Treatment B (CHF 718 pMDI 400 µg TDD))	adugiwbnyp(pcuihqmvfd) = phxsanajsx jllwmaenep (zgdcjdroju, vcwgtzcion - egckpcqsdl) View more
NCT01852513 (CTgov)	Phase 4	Rhinitis, Allergic, Seasonal	39	QNASL (QNASL Nasal Spray)	holtrqidmj(onitxvzito) = mpajdyhgis hmkrrrfjyz (gjfnjnuutg, 43.2) View more	-	09 Oct 2020
				Placebo nasal spray (Placebo Nasal Spray)	holtrqidmj(onitxvzito) = dmmwmctkow hmkrrrfjyz (gjfnjnuutg, 34.3) View more
NCT02499887 (CTgov)	Not Applicable	Pulmonary Disease, Chronic Obstructive \| Asthma	6	prednisone+albuterol (Standard of Care)	tobelaijbo(yqhnevfhak) = fhsysacbkm aknclttewh (ydmgrjllzr, bphncypsql - pmjcswuzcf) View more	-	04 Jun 2019
				beclamethasone dipropionate+prednisone+albuterol (Treatment)	tobelaijbo(yqhnevfhak) = fduguxtmvp aknclttewh (ydmgrjllzr, qubolcmvjb - jvspbxolxt) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Beclometasone Dipropionate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation